Malaria Vaccine Candidate Shows Long-term Efficacy in Mozambican children

A study published in the August 1 issue of the Journal of Infectious Diseases has shown for the first time that RTS,S, the world’s most clinically advanced malaria vaccine candidate, maintains protection during a 45 month follow-up period. The study conducted in 2022 Mozambican children age 1-4 years demonstrates that the RTS,S/AS02 vaccine is capable of reducing clinical episodes of malaria by 30 percent and severe malaria cases by 38 percent for at least 45 months following its administration.